文献速递肾癌与肾肿瘤

既往减瘤性肾切除术对同步转移性肾细胞癌患者接受阿维鲁单抗联合阿昔替尼或舒尼替尼治疗疗效的影响:JAVELIN Renal 101 3期试验事后分析

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
PubMed 文献 · Eur Urol · 2023-10-16

该事后分析基于JAVELIN Renal 101 3期试验,纳入412例初诊同步转移性(M1)晚期肾细胞癌初治患者,按既往是否行减瘤性肾切除术分组,评估阿维鲁单抗+阿昔替尼与舒尼替尼两臂的疗效。多变量Cox回归显示,阿维鲁单抗+阿昔替尼臂既往减瘤组较未减瘤组PFS的HR为0.79(95%CI 0.53-1.16),OS的HR为0.59(95%CI 0.38-0.93),ORR的OR为2.67(95%CI 1.32-5.41);舒尼替尼臂相应HR分别为1.15(95%CI 0.77-1.70)、0.86(95%CI 0.55-1.34),ORR的OR为2.02(95%CI 0.82-4.94)。原文指出需开展前瞻性研究探讨减瘤性肾切除术的潜在获益及合适时机。

要点

  • 阿维鲁单抗+阿昔替尼臂既往减瘤组较未减瘤组OS的HR为0.59(95%CI 0.38-0.93),PFS的HR为0.79(95%CI 0.53-1.16)。
  • 舒尼替尼臂既往减瘤组较未减瘤组PFS的HR为1.15(95%CI 0.77-1.70),OS的HR为0.86(95%CI 0.55-1.34)。
  • 阿维鲁单抗+阿昔替尼臂ORR的OR为2.67(95%CI 1.32-5.41),舒尼替尼臂为2.02(95%CI 0.82-4.94)。

核心结论

  • 在调整基线变量不平衡后,阿维鲁单抗+阿昔替尼臂既往减瘤组较未减瘤组OS的HR为0.59(95%CI 0.38-0.93),ORR的OR为2.67(95%CI 1.32-5.41),PFS的HR为0.79(95%CI 0.53-1.16)。
  • 舒尼替尼臂既往减瘤组较未减瘤组PFS、OS、ORR的HR/OR分别为1.15(95%CI 0.77-1.70)、0.86(95%CI 0.55-1.34)、2.02(95%CI 0.82-4.94)。
  • 原文指出需开展前瞻性研究探讨接受含免疫检查点抑制剂一线联合治疗患者中减瘤性肾切除术的潜在获益及合适时机。

研究设计与样本

  • JAVELIN Renal 101 3期试验的事后分析,纳入初诊M1期晚期肾细胞癌初治患者412例,按既往是否行减瘤性肾切除术分组。
  • 比较阿维鲁单抗+阿昔替尼臂与舒尼替尼臂的疗效,PFS和OS采用多变量Cox回归分析,ORR采用逻辑回归分析。
  • JAVELIN Renal 101试验在ClinicalTrials.gov注册号为NCT02684006。

主要发现

  • 阿维鲁单抗+阿昔替尼臂既往减瘤组较未减瘤组PFS的HR为0.79(95%CI 0.53-1.16),OS的HR为0.59(95%CI 0.38-0.93),ORR的OR为2.67(95%CI 1.32-5.41)。
  • 舒尼替尼臂既往减瘤组较未减瘤组PFS的HR为1.15(95%CI 0.77-1.70),OS的HR为0.86(95%CI 0.55-1.34),ORR的OR为2.02(95%CI 0.82-4.94)。
  • 原文患者摘要指出,阿维鲁单抗+阿昔替尼治疗前切除肾脏的患者结局优于未切除者,舒尼替尼治疗的两组结果更相似,但统计检验未发现显著差异。

临床怎么用

  • 原文结论未据此给出临床推荐,仅指出需前瞻性研究探讨减瘤性肾切除术的潜在获益及合适时机。

局限性

  • 原文为事后分析(post hoc analysis)。
  • 原文指出需开展前瞻性研究探讨减瘤性肾切除术的潜在获益及合适时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on the effects of prior cytoreductive nephrectomy (CN) in patients with renal cell carcinoma (RCC) with synchronous metastases (M1 disease) before immune checkpoint inhibitor (ICI) treatment are limited. In this post hoc analysis of treatment-naive patients with advanced RCC from the phase 3 JAVELIN Renal 101 trial, we assessed efficacy outcomes in the avelumab + axitinib and sunitinib arms in patients who were initially diagnosed with M1 disease (n = 412) grouped by prior CN (yes vs no). Progression-free survival (PFS) and overall survival (OS) were analyzed using multivariable Cox regression, and objective response rates (ORRs) were analyzed using logistic regression. After adjusting for imbalances in baseline variables, the hazard ratio (HR) for PFS in the prior CN versus no prior CN subgroup was 0.79 (95% confidence interval [CI] 0.53-1.16) in the avelumab + axitinib arm, and 1.15 (95% CI 0.77-1.70) in the sunitinib arm. The corresponding HRs for OS were 0.59 (95% CI 0.38-0.93) and 0.86 (95% CI, 0.55-1.34), and the odds ratios for ORR were 2.67 (95% CI 1.32-5.41) and 2.02 (95% CI 0.82-4.94), respectively. Prospective studies of the potential benefits of CN and its appropriate timing in patients receiving first-line treatment with ICI-containing combinations are warranted. PATIENT SUMMARY: This study looked at patients with kidney cancer whose disease had already spread outside the kidneys when it was first detected. We found that patients whose kidney had been removed before starting treatment with avelumab + axitinib had better outcomes than those whose kidney had not been removed. For patients treated with sunitinib, the results were more similar between the groups with and without prior kidney removal. However, statistical tests did not find any significant differences. The JAVELIN Renal 101 trial is registered on ClinicalTrials.gov as NCT02684006.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Grimm MO, Oya M, Choueiri TK, et al. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol. 2023. PMID: 37852850. doi:10.1016/j.eururo.2023.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。